AssetMark Inc’s Structure Therapeutics GPCR Stock Holding History

AssetMark Inc’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$123K	Buy	2,544 +449	+21%	+$30.7K	﹤0.01%	1480
2025 Q4	$146K	Sell	2,095 -289	-12%	-$11.8K	﹤0.01%	1380
2025 Q3	$66.8K	Sell	2,384 -493	-17%	-$9.82K	﹤0.01%	1538
2025 Q2	$59.7K	Buy	2,877 +820	+40%	+$18K	﹤0.01%	1507
2025 Q1	$35.6K	Sell	2,057 -214	-9%	-$5.24K	﹤0.01%	1526
2024 Q4	$61.6K	Buy	2,271 +953	+72%	+$33.8K	﹤0.01%	1368
2024 Q3	$57.8K	Buy	1,318 +719	+120%	+$27.8K	﹤0.01%	1255
2024 Q2	$23.5K	Buy	+599	New	+$24.6K	﹤0.01%	1358

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

AssetMark Inc's GPCR Position: Q1 2026 in Review

AssetMark Inc increased its Structure Therapeutics (GPCR) stake by 21% in Q1 2026, buying an estimated $30.7K and bringing the position to 2,544 shares worth $123K. The position accounts for ﹤0.01% of the portfolio, ranked #1480.

AssetMark Inc first reported a position in GPCR in Q2 2024 and has held it in 8 quarters since. The position peaked at $146K in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

AssetMark Inc held 2,544 shares of Structure Therapeutics worth $123K as of Q1 2026.
AssetMark Inc bought 449 Structure Therapeutics shares in Q1 2026, an estimated $30.7K.
Structure Therapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q1 2026, its #1480 holding.
AssetMark Inc first reported a position in Structure Therapeutics in Q2 2024 and has held it in 8 quarters since.
AssetMark Inc's Structure Therapeutics position peaked at $146K in Q4 2025.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on AssetMark Inc's 13F filing for Q1 2026, filed 6 May 2026.